본문 바로가기

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY13 · #1.7588359211042812e+16 · 2021
피인용
Web of Science 15Scopus 15
FWCI (Scopus)
0.55
JCR IF
JCR 2020 8.168
ISSN
1758-8340

저자

  1. Han, Hye Sook제1저자Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Internal Med, Coll Med, Cheongju, Chungcheongbuk, South Korea
  2. Kim, Bum JunHallym Univ, Sacred Heart Hosp, Dept Internal Med, Coll Med, Anyang Si, Gyeonggi Do, South Korea
  3. Jee, Hee-JungKorea Univ, Coll Med, Dept Biostat, Seoul, South Korea
  4. Ryu, Min-HeeUniv Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea
  5. Park, Se HoonSungkyunkwan Univ, Dept Med, Div Hematol Oncol, Samsung Med Ctr, Seoul, South Korea
  6. Rha, Sun YoungYonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
  7. Kim, Jong GwangKyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Oncol Hematol, Daegu, South Korea
  8. Bae, Woo KyunChonnam Natl Univ, Dept Internal Med, Med Sch, Hwasun, Jeollanam Do, South Korea
  9. Lee, Keun-WookSeoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea
  10. Oh, Do-YounSeoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea
  11. Kim, In-HoCatholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea
  12. Sym, Sun JinGachon Univ Gil Hosp, Dept Internal Med, Div Hematol & Oncol, Incheon, South Korea
  13. 오소연Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
  14. Kim, Hyeong SuHallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
  15. Byun, Ji-HyeHlth Insurance Review & Assessment Serv, Innovat Res Dept, Wonju, South Korea
  16. Kim, Dong SookHlth Insurance Review & Assessment Serv, Review & Assessment Res Dept, Wonju, South Korea
  17. Suh, Young JuInha Univ, Coll Med, Dept Biomed Sci, Incheon, South Korea
  18. An, HyongginKorea Univ, Coll Med, Dept Biostat, Seoul, South Korea
  19. Zang, Dae Young교신저자Hallym Univ, Dept Internal Med, Hallym Univ Sacred Heart Hosp, Coll Med, 22 Gwanpyeong Ro 170 Beongil Dongan Gu, Anyang Si 14068, Gyeonggi Do, South Korea

초록

Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study cohorts focused on ramucirumab plus paclitaxel in gastric cancer are limited. Methods: The study population comprised all patients with gastric or GEJ cancer who received ramucirumab plus paclitaxel in South Korea between 1 May 2018 and 31 December 2018. We included patients with advanced gastric or GEJ adenocarcinoma and disease progression after first-line platinum and fluoropyrimidine-containing combination chemotherapy. Results: In total, 1063 patients were included in the present study. The objective response rate and disease control rate were 15.1% and 57.7%, respectively. The median progression-free survival was 4.03months (95% confidence interval, 3.80-4.27) and the median overall survival was 10.03months (95% confidence interval, 9.33-10.73). Grade 3 or higher treatment-related adverse events with incidence of 5% were neutropenia (35.1%) and anemia (10.5%). Based on multivariable analysis, overall survival was negatively associated with Eastern Cooperative Oncology Group performance status 2, weight loss 10% in the previous 3months, GEJ of primary tumor, poor or unknown histologic grade, number of metastatic sites 3, presence of peritoneal metastasis, no prior gastrectomy, and time to second-line since first-line treatment <6months. Conclusion: Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

키워드

gastric cancerpaclitaxelramucirumabreal-world dataRANDOMIZED CLINICAL-TRIALPHASE-III1ST-LINE THERAPYDOUBLE-BLINDOPEN-LABELCANCERCHEMOTHERAPYRAINBOWCOMBINATIONEAST

식별자

Scopus EID
2-s2.0-85115063816
WoS UID
000697412800001